Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Rasburicase and Allopurinol in Hematologic Malignancies
NCT01564277Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2011
- Primary completion
- May 2015
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rasburicase in tumor lysis syndrome (TLS), hyperuricemia, sponsored by Roswell Park Comprehensive Cancer Center. Started Sep 2011; status: terminated.
02
Drugs
rasburicase
03
Conditions
tumor lysis syndrome (TLS)hyperuricemia
Beyond the preview
Go deeper on NCT01564277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01564277.